Weight-Loss Drug Zepbound Faces Supply Issues
Another popular weight-loss drug is in short supply. Doses of tirzepatide (Zepbound) are few and far between, experts told MedPage Today, although the injectable has not been listed in the FDA Drug Shortage Database as of today. Another version of tirzepatide, for type 2 diabetes (Mounjaro), has been on the FDA shortage list since December […]
Tirzepatide Wins FDA Approval for Weight Loss
The FDA approved tirzepatide (Zepbound), the latest injectable for chronic weight management in adults, the agency announced on Wednesday. The combination glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist is indicated for adults with obesity or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. Eli Lilly’s […]
First GLP-1/GIP Receptor Agonist OK’d for Type 2 Diabetes
The FDA approved first-in-class tirzepatide (Mounjaro) for patients with type 2 diabetes, the agency announced on Friday. Tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) agonist, is available at three dose levels (5 mg, 10 mg, and 15 mg), should be administered via injection once weekly, and is indicated as an adjunct to diet […]